New drug combo trial seeks better tolerability for Tough-to-Treat cervical cancer
NCT ID NCT07143292
Summary
This study is testing if using a lower dose of the drug famitinib, when combined with another drug called camrelizumab, can reduce side effects while still controlling cancer growth. It will involve 120 women with cervical cancer that has returned or spread and is no longer curable with standard treatments. The main goal is to see if a lower dose is easier to tolerate and how long it keeps the cancer from getting worse.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.